Richmond, Virginia biopharmaceutical company Insmed Incorporated has announced a "business combination" with Transave, making Transave a wholly-owned subsidiary. The company also announced plans for Phase 3 trials of Arikace inhalation solution for the treatment of pseudomonas infections in CF patients and for the treatment of non-TB mycobacteria lung infections in the second half of 2011. Read the company’s press release.
Insmed acquires Transave and its Arikace inhaled liposomal amikacin
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
